Cheyenne, WY, February 11, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH Under the engagement, Shah Teelani & Associates will oversee
Cheyenne, WY, January 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – CS Diagnostics Corp.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Thomas Fahrhoefer CEO | OTC PINK Exchange | 33852L202 CUSIP |
| US Country | 1 Employees | - Last Dividend | 3 Aug 2023 Last Split | - IPO Date |
CS Diagnostics Corp. is a leading manufacturer and distributor of medical products catering to various sectors of the healthcare industry, including medicine, radiology, cardiology, and radiation therapy. With its roots in Germany, the company has successfully expanded its operations on an international scale. Originally established as FlashZero Corp. in 1996, it rebranded to CS Diagnostics Corp. in August 2023, reflecting its evolution and dedication to the field of diagnostics. The company's headquarters are situated in Neuss, Germany, positioning it strategically within one of Europe's most significant medical and pharmaceutical hubs. As a pharmaceutical wholesaler, CS Diagnostics Corp. plays a pivotal role in the healthcare supply chain, ensuring the availability of essential medical products and services across the globe.
The company's product portfolio is diverse, catering to a wide range of needs within the healthcare sector: